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Oncolytic virus (OV) therapy takes advantage of common cancer characteristics, such as defective type I
interferon (IFN) signaling, to preferentially infect and kill cancer cells with viruses. Our recent study
(Murphy et al., 2012. J. Virol. 86, 3073–87) found human pancreatic ductal adenocarcinoma (PDA) cells
were highly heterogeneous in their permissiveness to vesicular stomatitis virus (VSV) and suggested at
least some resistant cell lines retained functional type I IFN responses. Here we examine cellular
responses to infection by the oncolytic VSV recombinant VSV-DM51-GFP by analyzing a panel of 11
human PDA cell lines for expression of 33 genes associated with type I IFN pathways. Although all cell
lines sensed infection by VSV-DM51-GFP and most activated IFN-a and b expression, only resistant cell
lines displayed constitutive high-level expression of the IFN-stimulated antiviral genes MxA and OAS.
Inhibition of JAK/STAT signaling decreased levels of MxA and OAS and increased VSV infection,
replication and oncolysis, further implicating IFN responses in resistance. Unlike VSV, vaccinia and
herpes simplex virus infectivity and killing of PDA cells was independent of the type I IFN signaling
proﬁle, possibly because these two viruses are better equipped to evade type I IFN responses. Our study
demonstrates heterogeneity in the type I IFN signaling status of PDA cells and suggests MxA and OAS as
potential biomarkers for PDA resistance to VSV and other OVs sensitive to type I IFN responses.
& 2012 Elsevier Inc. All rights reserved.Introduction
Oncolytic virus (OV) therapy utilizes viruses with naturally
inherited or engineered properties enabling them to preferen-
tially infect and kill cancer cells (Breitbach et al., 2010; Russell
and Peng, 2007; Va¨ha¨-Koskela et al., 2007). This approach utilizes
common cancer characteristics such as defective innate immune
responses or abnormalities in regulation of mRNA translation
or cellular signaling pathways to provide the needed cancer
speciﬁcity.
Vesicular stomatitis virus (VSV) has been successfully used as
an OV in preclinical models of a number of malignancies
[reviewed in (Barber, 2004; Hastie and Grdzelishvili, 2012)]. As
a result, a clinical trial using VSV against hepatocellular carci-
noma is currently in progress (Clinicaltrials.gov, 2012, Trial ID:
NCT01628640). A number of oncolytic VSV recombinants have
been developed to address safety concerns relating to the use of
wild-type (wt) VSV. In one of these, VSV-DM51-GFP, a deletion ofll rights reserved.
hvili).
.the methionine at amino acid position 51 of the matrix (M)
protein prevents shut down of cellular gene expression (Ahmed
et al., 2003), providing enhanced safety, including an absence of
neurotoxicity in vivo, while still demonstrating good oncolytic
potential (Ahmed et al., 2008; Ebert et al., 2005; Goel et al., 2007;
Kelly et al., 2010; Stojdl et al., 2003; Wollmann et al., 2010; Wu
et al., 2008).
We recently tested wild-type (wt) VSV and two non-neurotropic
VSV recombinants (including VSV-DM51-GFP), as well as recombi-
nant Sendai virus, recombinant respiratory syncytial virus and two
recombinant adenoviruses against a panel of human pancreatic
ductal adenocarcinoma (PDA) cell lines (Murphy et al., 2012). PDAs
are highly aggressive and metastatic (Stathis and Moore, 2010) and
represent about 95% of pancreatic cancers. PDA is one of the most
lethal abdominal malignancies (Farrow et al., 2008; Lindsay et al.,
2005), and current treatments are largely ineffective (Stathis and
Moore, 2010). Our study demonstrated VSV is a promising oncolytic
agent against PDA, as the majority of PDA cell lines tested were
highly susceptible to infection and killing by VSV recombinants
(Murphy et al., 2012). However, ﬁve PDA cell lines as well as the
non-malignant HPDE cell line were resistant to most VSV recombi-
nants, (wt VSV, VSV-DM51-GFP, and VSV-p1-GFP), at least at low
multiplicities of infection (MOI), the expected scenario in vivo.
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were able to both secrete and respond to type I interferon (IFN),
suggesting intact type I IFN responses contributed to their
resistance phenotype (Murphy et al., 2012). While other mechan-
isms have been noted (Hastie and Grdzelishvili, 2012), type I IFN
sensitivity is believed to be a major factor contributing to VSV’s
oncoselectivity, as it is unable to efﬁciently infect healthy cells. In
contrast, the majority of cancer cells are thought to be defective in
type I IFN production and responses (Barber, 2004; Hastie and
Grdzelishvili, 2012; Lichty et al., 2004), as IFN responses are
generally anti-proliferative, anti-angiogenic and pro-apoptotic
(Wang et al., 2011), conditions unfavorable for tumor formation.
However, some cancer cells are known to produce and/or respond
to type I IFN (Naik and Russell, 2009; Stojdl et al., 2000), including
some mesotheliomas (Saloura et al., 2010), melanomas (Linge
et al., 1995; Wong et al., 1997), lymphomas (Sun et al., 1998),
bladder cancers (Matin et al., 2001), renal cancers (Pfeffer et al.,
1996), and possibly other cancers (Stojdl et al., 2003).
Here we further analyze a panel of 11 clinically relevant
human PDA cell lines for the presence of type I IFN response,
determine the functionality of that response in resistance to
VSV-DM51-GFP and attempt to identify an RNA and/or protein
where presence or absence was well correlated with resistance
to this virus. The cell lines most resistant to VSV-DM51-GFP
infection were shown to constitutively express at least some
interferon stimulated genes (ISGs), including the antiviral genes
MxA and OAS. Inhibition of the JAK/STAT signaling pathways
reduced ISG expression and improved VSV-DM51-GFP infectivity,
replication and oncolysis, implicating IFN responses in resistance.Results
Identiﬁcation of antiviral genes constitutively expressed in PDA cells
resistant to VSV
Our recent evaluation of VSV against human PDA cell lines
revealed substantial diversity in their susceptibility to VSV-
mediated oncolysis, which correlated with permissiveness to
VSV infection (Murphy et al., 2012). Most resistant PDA cell lines
were both sensitive to IFN-a treatment (which strongly inhibitedTable 1
Human pancreatic cell lines used in this study and a summary of VSV-DM51-GFP susc
Human cell line Origina VSV-DM51
resistancec
IRF7 IFN-a
Lowd Highe VSVf Low H
Capan-1 Liver
metastasis
– x x
MIA PaCa-2 Primary PDA – x x x
Panc-1 Primary PDA – x x
Capan-2 Primary PDA – x x
AsPC-1 Ascites – x x
Suit2 Liver
metastasis
– x x
T3M4 LN metastasisb – x x
HPDE Non-malignant þ x x
CFPAC-1 Primary PDA þþ x x
HPAC Primary PDA þþ x x
Hs766T LN metastasis þþþ x x
HPAF-II Primary PDA þþþ x x
a All cell lines (except for non-malignant HPDE) have PDA origin.
b LN, lymph node.
c –, susceptible; þ , intermediate; þþ, resistant; þþþ highly resistant.
d mRNA expression undetectable or barely detectable.
e mRNA robustly expressed.
f mRNA expression increases upon VSV-DM51-GFP infection.VSV infection) and capable of secreting IFN-b following VSV
infection (Murphy et al., 2012), suggesting resistant PDA cell lines
may retain active type I IFN signaling. In this study, we assessed
type I IFN related cellular responses to VSV-DM51-GFP infection
on a molecular level in a panel of 11 clinically relevant human
PDA cell lines (Table 1), and examined the role of the JAK/STAT
signaling pathways in the observed resistance phenotypes.
Expression of 33 human genes (Supplementary Table 1) respon-
sible for sensing viral infection [e.g., retinoic-acid-inducible gene I
(RIG-I)], activating production of type I IFNs [e.g., IFN-regulatory
factor (IRF) 3], sensing IFNs [e.g., interferon alpha/beta receptor 1
(IFNAR1)] and inducing an antiviral state in cells [e.g., myxovirus
(inﬂuenza) resistance 1 (MxA)] was assessed. Because we wanted to
focus on a speciﬁc set of genes, this was done using semi-quantitative
RT-PCR. Genes were selected based on their importance in type I IFN
responses. Some of these genes, particularly ISGs, are expressed
in response to type I IFNs, and are expected to be upregulated in
cells with intact type I IFN signaling following VSV infection. Also,
differential expression of RIG-I (Wilden et al., 2009), myeloid differ-
entiation primary response protein MyD88 (MyD88) (Wongthida
et al., 2011), IRF3 (Marozin et al., 2008; Wilden et al., 2009), IRF7
(Wilden et al., 2009) IFNAR1/2 (Saloura et al., 2010; Zhang et al.,
2010), tyrosine-protein kinase JAK1 (JAK1) (Dunn et al., 2005), signal
transducer and activator of transcription (STAT) 1 (Lee et al., 1997;
Sun et al., 1998), IRF9 (Matin et al., 2001; Saloura et al., 2010), MxA
(Monsurro et al., 2010; Paglino and van den Pol, 2011), 20-50-
oligoadenylate synthetase (OAS) (Monsurro et al., 2010; Saloura
et al., 2010), and interferon-induced, double-stranded RNA-activated
protein kinase (PKR) (Saloura et al., 2010) has been previously
reported to correlate to or be responsible for the virus or IFN resis-
tance phenotypes of various cancer cell types.
PDA cells were mock infected or infected with VSV-DM51-GFP for
4 h, and total RNA was isolated and analyzed for expression of
candidate genes. As shown in Fig. 1, most analyzed genes (including
all additional genes listed in Supplementary Table 1 but not shown in
Fig. 1) were expressed at similar levels in all cell lines regardless of
the VSV resistance phenotype. However, several genes were clearly
differentially expressed. Among genes associated with sensing viral
infection, IRF7 was down regulated in Capan-1 and MIA PaCa-2, both
highly susceptible to VSV-mediated cell death (Murphy et al., 2012).
In agreement with a key role for IRF7 in the expression of type I IFNseptibility and expression of select mRNAs.
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Fig. 1. mRNA expression of IFN related genes. Cells were mock infected () or infected (þ) with VSV-DM51-GFP at MOI 10 CIU/cell and harvested at 4 h p.i. Extracted
mRNA was reverse transcribed and then analyzed by semi-quantitative PCR for the indicated genes. PCR product sizes are indicated on the right.
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also lacked IFN-a and b gene expression even after VSV-DM51-GFP
infection (Fig. 1). Interestingly, reduced expression of IRF-7 has
recently been linked to increased metastasis in breast cancer, with
disruption of IFN signaling identiﬁed as the primary cause (Bidwell
et al., 2012).
Although in our previous study only 4 cell lines (HPAF-II, HPAC,
Hs766T and non-malignant HPDE) produced detectable levels ofsecreted IFN-b at 18 h p.i. (Murphy et al., 2012), here VSV-DM51-
GFP at 4 h p.i. induced production of IFN-b mRNA in all cell lines
except Capan-1 and MIA PaCa-2 (Fig. 1). Most cell lines (again, with
the exception of Capan-1 and MIA PaCa-2) also showed constitutive
expression of IFN-a mRNA that was only marginally increased upon
VSV-DM51-GFP infection at 4 h p.i. The highest constitutive levels of
IFN-a mRNA were seen in three of the resistant cell lines, HPAF-II,
Hs766T and HPAC. While differences in IRF7, IFN-a and IFN-b mRNA
M. Moerdyk-Schauwecker et al. / Virology 436 (2013) 221–234224expression were observed, these alone could not discriminate
between the phenotypes of PDA cells based on their permissiveness
to VSV.
As shown in Fig. 1, differences were not seen in the expression
of the IFN-a/IFN-b receptor (IFNAR1 and IFNAR2), or the major
components of IFN type I signal transduction (JAK1, STAT1, STAT2
and IRF9) at the transcriptional level. However, there was great
variability in the expression of two ISGs, MxA and OAS. Impor-
tantly, there was a correlation between virus resistance pheno-
type and the levels of MxA and OAS mRNA. MxA and OAS were at
the highest levels in the resistant cell lines HPAF-II, Hs766T, HPACFig. 2. mRNA and protein expression of IFN related genes. Cells were mock infected,
5000 U/ml IFN-a. Cells were harvested at 12 h p.i. and mRNA was reverse transcribed an
western blot for the indicated protein. PCR (nt) and protein (kDa) product sizes are inand non-malignant HPDE; at lower levels (especially in the
absence of infection) in less resistant Suit2, T3M4 and CFPAC-1;
and minimally produced in the remaining cell lines, all of which
are highly susceptible to VSV-DM51-GFP infection. Interestingly,
while MxA and OAS had variable mRNA expression in different
PDA cell lines a 4 h p.i., a similar pattern was not observed with
other antiviral ISGs such as PKR, RNAse L, ISG56 and viperin.
To conﬁrm the association of MxA and OAS expression with the
resistance of PDA cells to VSV-DM51-GFP, we conducted a similar
experiment with a representative group of 7 cell lines mock-treated,
treated with IFN-a, or infected with VSV-DM51-GFP for 12 h toinfected with VSV-DM51-GFP (indicated as VSV) at MOI 10 CIU/cell or treated with
d analyzed by semi-quantitative PCR or cell lysates were prepared and analyzed by
dicated on the right.
Table 2
Summary of VSV-DM51-GFP susceptibility and expression of select proteins.
Human cell line VSV-DM51 resistancea IRF3-p STAT1-p MxA OAS
Lowb Highc VSVd IFN-ae Low High VSV IFN-a Low High VSV IFN-a Low High VSV IFN-a
MIA PaCa-2 – x x x x x x x
AsPC-1 – x x x x x x x x x
Suit2 – x x x x x x x x x x
HPDE þ x x x x x x x
HPAC þþ x x x x x x x x
Hs766T þþþ x x x x x x x
HPAF-II þþþ x x x x x x x
a –, susceptible; þ , intermediate; þþ, resistant; þþþ highly resistant.
b Protein expression undetectable or barely detectable.
c Protein robustly expressed.
d Protein Expression increases upon VSV-DM51-GFP infection.
e Protein expression increases upon IFN-a treatment.
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(Fig. 2), we conducted not only mRNA analysis (as in Fig. 1), but also
western blot analysis to determine protein levels of the analyzed
genes. In addition to the non-malignant HPDE, which has inter-
mediate resistance, we analyzed two highly resistant (HPAF-II,
Hs766T), one intermediate (HPAC) and three susceptible cell lines
(MIA PaCa-2, AsPC-1, Suit2). Susceptibility to viral infection
was conﬁrmed based on virus-directed GFP expression, which we
have previously shown correlates well with viral protein synthesis
(Murphy et al., 2012). Importantly, among susceptible cell lines, we
selected two cell lines (AsPC-1 and Suit2) previously shown to be
responsive to IFN-a treatment and one cell line (MIA PaCa-2) which
was completely resistant to IFN-a treatment (Murphy et al., 2012).
As shown in Fig. 2, a correlation was observed between MxA and
OAS accumulation (mRNA and protein) and the resistance pheno-
type of PDA cell lines. Again, all resistant cell lines showed
constitutive expression of MxA and OAS even in the absence of
virus infection or IFN treatment. The expression of MxA and OAS is
controlled via STAT1 and STAT2 activation. Although variations in
mRNA levels were not observed for STAT1 and STAT2 (Figs. 1 and 2),
we tested whether phosphorylation of the protein products differed
in VSV permissive and resistant cell lines. As shown in Fig. 2,
although most cell lines had detectable levels of phosphorylated
STAT1 protein following 12-h IFN-a treatment, the highest levels of
STAT1 activation following VSV-DM51-GFP infection were observed
in HPAF-II, Hs766T and HPAC, all of which are resistant. Also, lower
but detectable levels of phosphorylated STAT1 in untreated cells
were detected in these three cell lines and in HPDE, which may at
least partially explain the constitutive expression of MxA and OAS in
these cell lines. Among the susceptible cell lines, STAT1 was
activated in AsPC-1 and to a much lesser degree in Suit2 upon
infection, but not in MIA PaCa-2, although it was strongly activated
in MIA PaCa-2 upon IFN treatment. A similar pattern of protein
phosphorylation was observed for STAT2 (Fig. 2).
To test whether PDA cell lines susceptible to VSV-DM51-GFP are
able to detect VSV infection, we analyzed phosphorylation of IRF3.
Interestingly, all tested PDA cell lines showed increased IRF3 phos-
phorylation in response to infection (Fig. 2), suggesting the upstream
components of the RIG-I pathway are functional. In agreement with
this observation, type III IFN-lmRNAwas expressed in all cell lines in
response to VSV-DM51-GFP infection (Figs. 1 and 2). However, at
12 h p.i., MIA PaCa-2 still failed to activated IFN-a and IFN-b mRNA
expression.
Key differences in mRNA and protein expression are summarized
in Tables 1 and 2, respectively. Together, our gene expression data
suggest all tested PDA cell lines are capable of sensing VSV infection,
most produce type I IFNs, and most are capable of sensing IFN.However, resistant cell lines were characterized by constitutive
expression of at least two ISGs, MxA and OAS, which possibly
contribute to their resistance phenotype.
Improved oncolysis of resistant PDA cells by combination treatment
with JAK inhibitor I
Gene expression data showed a correlation between resistance to
VSV-DM51-GFP infection and elevated expression of at least some
ISGs. Therefore, a possible causative role for these and other ISGs in
the resistance phenotype was tested by inhibition of the JAK/STAT
signaling pathways responsible for activation of ISG expression, using
a general inhibitor of JAKs, JAK Inh. I. First, the effectiveness of the JAK
Inh I treatment was conﬁrmed by western blot for p-STAT1, MxA and
OAS. Twenty-four hours treatment with 0.5 or 2.5 mM JAK Inh. I
completely eliminated STAT1 phosphorylation and markedly reduced
MxA and OAS protein levels (data not shown). The same treatments
for 48 h, followed bymock infection or infection with VSV-DM51-GFP
at MOI 10 (based on 4T-1) for 16 h, further reduced MxA and OAS
protein to below detectable levels in uninfected cells and sharply
reduced them in infected cells (Fig. 3). In general, MxA and OAS
expression in mock treated cells was consistent with that seen in
Fig. 2, despite different treatment conditions, although some variation
was noted (e.g., MxA levels in HPAC cells).
When new infectious virus particle production was deter-
mined following JAK Inh. I treatment, by collecting supernatants
and titering them on BHK-21, increases were seen for the
resistant cell lines (CFPAC, HPAC, HPAF-II, HPDE and Hs766T)
(Table 3). Consistent with the improvement in virus production, a
robust increase in viral protein accumulation was seen for the
resistant cell lines CFPAC, HPAC, HPDE and Hs766T and a slight
increase was seen for the resistant cell line HPAF-II. Treatment
also caused a modest increase in viral protein accumulation in
Suit2, a cell line we classify as susceptible. While titers were well
correlated with viral protein as determined by western blot, this
was not absolute, possibly due to low viral titers in some cell lines
(especially HPAF-II) and cell line variations in virus replication
kinetics and infectious/non-infectious particle ratios.
Our previous study showed a correlation between suscept-
ibility of PDA cells to VSV-mediated cell death and the relative
infectivity of VSV on different PDA cell lines (Murphy et al., 2012).
To determine if inhibition of JAK/STAT signaling improved VSV-
DM51-GFP infectivity in resistant cells, VSV-DM51-GFP was
titered on mock treated cells or cells treated with JAK Inh. I for
48 h. Consistent with previous results (Murphy et al., 2012), titers
were lower on resistant cell lines (CFPAC, HPAC, HPAF-II, HPDE,
Hs766T) than susceptible cell lines (AsPC-1, MIA PaCa-2, Suit2).
Fig. 3. Effect of JAK/STAT signaling inhibition on p-STAT1, MxA and OAS expression. Cells were mock (DMSO) treated or treated with 0.5 or 2.5 mM JAK Inh I for 48 h
prior to infection with VSV-DM51-GFP at MOI 10 CIU/cell. Cells were harvested at 16 h p.i. and cell lysates were prepared and analyzed by western blot for the indicated
proteins. n, position of M protein in JAK Inh. I treated HPAF-II cells.
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ever, some improvement in titer was observed on HPAC and
HPAF-II with treatment (Fig. 4), although it was statistically
signiﬁcant only for HPAF-II. What was observed for all resistant
cell lines, with the possible exception of HPDE, was a clear
increase in plaque size upon JAK Inh. I treatment (data notshown). An increase in plaque size was also observed on the
susceptible AsPC-1 cell line at the highest inhibitor concentration.
This data suggests that while activation of the JAK/STAT pathways
contributes to resistance to VSV-DM51-GFP in most resistant cell
lines, other factors may contribute to the differences in VSV titers
in various PDA cell lines.
M. Moerdyk-Schauwecker et al. / Virology 436 (2013) 221–234 227To determine if the improvement in new infectious particle
production and plaque size translated into improved cell killing,
cells were pretreated with JAK Inh. I for 48 h and infected with
VSV-DM51-GFP at MOI 1 (based on 4T-1). Virus-directed GFP
expression was measured every 24 h and cell viability was
determined at the end of ﬁve days by MTT assay. GFP expression
increased upon JAK Inh. I treatment for all ﬁve resistant cell lines
plus the susceptible cell lines AsPC-1 and Suit2 (Fig. 5). No
increase was seen for the susceptible cell line MIA PaCa-2. When
cell viability was determined (Fig. 6A), a statistically signiﬁcant
increase in VSV-mediated cell death was seen with inhibitor
treatment for HPDE, the expected outcome for a ‘‘normal’ (non-
malignant) cell line. Importantly, a similar result was observed in
the VSV-resistant CFPAC-1, HPAC and Hs766T cell lines at least at
the highest concentration of inhibitor (2.5 mM), suggesting an
involvement of JAK/STAT signaling in the resistance phenotype of
these cell lines. Treatment with JAK Inh. I alone generally did notTable 3
New infectious virus particle production at 16 h p.i. after 48 h pre-treatment with
JAK Inh. I.
PDA Cells Treatmenta Yieldb Ratioc
AsPC-1 VSV 8.4107 1
VSVþ0.5 mM JAK Inh. I 4.2108 5
VSVþ2.5 mM JAK Inh. I 2.6108 3
CFPAC-1 VSV 1.3106 1
VSVþ0.5 mM JAK Inh. I 2.6107 20
VSVþ2.5 mM JAK Inh. I 2.1107 16
HPAC VSV 2.6106 1
VSVþ0.5 mM JAK Inh. I 3.1107 12
VSVþ2.5 mM JAK Inh. I 7.9106 3
HPAF-II VSV 2.0104 1
VSVþ0.5 mM JAK Inh. I 1.3106 64
VSVþ2.5 mM JAK Inh. I 5.2106 256
Hs766T VSV 4.1104 1
VSVþ0.5 mM JAK Inh. I 2.1107 512
VSVþ2.5 mM JAK Inh. I 1.0107 256
MIA PaCa-2 VSV 4.2108 1
VSVþ0.5 mM JAK Inh. I 5.0108 1.2
VSVþ2.5 mM JAK Inh. I 2.1108 0.5
Suit2 VSV 2.1108 1
VSVþ0.5 mM JAK Inh. I 1.3108 0.6
VSVþ2.5 mM JAK Inh. I 8.4107 0.4
HPDE VSV 6.1104 1
VSVþ0.5 mM JAK Inh. I 1.3108 2048
VSVþ2.5 mM JAK Inh. I 1.3108 2048
a ‘‘VSV’’ indicates VSV-DM51-GFP.
b Virus was collected from the indicated cell line and titer was determined on
BHK-21 cells.
c Ratio of virus yield on JAK Inh. I treated cells to mock treated cells.
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Fig. 4. Effect of JAK/STAT signaling inhibition on PDA cell susceptibility to VSV-DM5
48 h prior to infection with serial dilutions of VSV-DM51-GFP. At 17 hpi, VSV-DM51-GF
ratio to the mock treated titer, with the mock treated titer indicated. Titers were done in
compared using a 1-way ANOVA followed by the Bonferroni posttest for multiple comcause a loss in cell viability, as measured by MTT, although a
statistically signiﬁcant decrease was seen for Hs766T at the
lowest concentration only, HPDE at the highest concentration
only and Suit2 at both concentrations. Consistent with the
possible cytotoxic effects of JAK Inh. I on Suit2 and HPDE, virus-
directed expression of GFP dropped at the higher concentration
(2.5 mM) compared to the lower concentration (0.5 mM), although
it still exceeded expression in untreated cells (Fig. 5). Interest-
ingly, in some cases, most notably HPAF-II, JAK Inh I caused a
signiﬁcant increase in MTT signal in uninfected cells. This may be
due to an increase in the number of viable cells or due to an
increase in mitochondrial activity (the actual parameter mea-
sured by the MTT assay), which can be caused by stress. To more
speciﬁcally look at this question, the experiment was repeated
with HPAF-II with a parallel plate used for cell counting. While
less dramatic than in the previous experiment, treatment with
2.5 mM JAK Inh I alone did cause a statistically signiﬁcant increase
in MTT signal (Fig. 6B). However, this treatment did not change
the number of viable cells number (Fig. 6B). This experiment also
conﬁrmed that treatment of HPAF-II with 2.5 mM JAK Inh. I caused
an increase in cell killing by VSV-DM51-GFP.
Susceptibility of PDA cells to other viruses
The ability of VSV-DM51-GFP to initiate infection on the PDA
and HPDE cell lines was assessed by performing a plaque assay
using serial dilutions of virus. Permissiveness was expressed as a
ratio of the viral titer on PDA cell line to the titer on Vero cells
with higher numbers indicating greater permissiveness and cell
lines listed in order of permissiveness (Fig. 7). In conﬁrmation of
our previous results, the ﬁve resistant cell lines (CFPAC, HPAC,
HPAF-II, HPDE and Hs766T) showed the least susceptibility to
VSV-DM51-GFP, in terms of both plaque size and number, and
formed a distinct cluster from the susceptible cell lines. All of
these highly resistant cells constitutively express at least some
ISGs, including MxA and OAS, not seen in the more susceptible
cell lines. In contrast, the two PDA cell lines where VSV-DM51-
GFP formed the largest plaques (MIA PaCa-2 and Capan-1) are the
only cell lines that fail to express both IFN-a and b following VSV-
DM51-GFP infection (Figs. 1 and 2). Previous studies showed that
VSV is highly sensitive to type I IFN responses, an effect even
more pronounced in VSV-DM51-GFP as a result of the methionine
51 deletion in the M protein (Black et al., 1993; Coulon et al.,
1990; Stojdl et al., 2003). If indeed the susceptibility proﬁle of
these cells is at least in part determined by their type I IFN status,
it would be expected that viruses capable of evading the host
type I IFN response would display a different proﬁle. To test this
hypothesis, we used two large DNA viruses unrelated to VSV,Hs766T MIA PaCa-2 Suit2 HPDE
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Fig. 5. Effect of JAK/STAT signaling inhibition on virus-directed GFP expression. Cells were mock (DMSO) treated or treated with 0.5 or 2.5 mM JAK Inh. I for 48 h prior
to infection with VSV-DM51-GFP at MOI 1 CIU/cell. GFP ﬂuorescence following infection was measured at 24 h intervals.
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(a herpesvirus), both of which have been shown to evade type I
IFN antiviral responses (Paladino and Mossman, 2009; Perdiguero
and Esteban, 2009). While the speciﬁc VV and HSV-1 viruses used
in this experiment are not used as OVs, other recombinants based
on VV and HSV have been developed for that purpose. When
VVT7 and HSV-1 were titered on PDA cell lines, there was not a
correlation between the permissiveness of cells to these two
viruses (Fig. 7) and their type I IFN status (Figs. 1 and 2), as
indicated by the different ordering of these cells lines by permis-
siveness as compared to VSV-DM51-GFP. This is consistent with
the greater abilities of VVT7 and HSV-1 to evade this pathway.
The degree of curvature of the graphs in Fig. 7 indicates the
variability in cell line permissiveness to the viruses. The varia-
bility in cell line permissiveness was similar for VSV-DM51-GFP
and HSV-1, although they differed in which cell lines were
susceptible or resistant. In contrast, the range was much smaller
for VVT7 with the exception of highly resistant (to VVT7) Capan-2.
To determine if susceptibility of the PDA cells to these three
viruses extended to cell killing, cell viability was determined by
MTT assay at 5 d p.i. following infection with VSV-DM51-GFP,
VVT7 or HSV-1 at MOI 1 or 0.01 as determined by titration on
Vero cells that support robust replication of all three viruses
(Fig. 8). For VSV-DM51-GFP, results closely mimicked those
reported in our previous study (Murphy et al., 2012). However,
all VSV-resistant cell lines (CFPAC-1, HPAC, Hs766T, HPAF-II
and HPDE), were more effectively killed by HSV-1 and VVT7 than
VSV-DM51-GFP at MOI 1, and this was also true for most of those
cell lines at MOI 0.01. Importantly, HSV-1 and VVT7 did not
demonstrate superior oncolytic abilities in all cell lines (e.g.,
AsPC-1 and Capan-2 at MOI 0.01). Although we cannot rule out
that other (IFN-unrelated) factors inﬂuenced cell susceptibility tothese three viruses, the results are consistent with type I IFN
responses being at least a factor in determining resistance to
VSV-DM51-GFP infection.Discussion
In this study, we demonstrated on a molecular level that the
resistant cell lines tested have functional type I IFN responses
similar to those observed in the non-malignant HPDE cell line.
Importantly, we found that, unlike susceptible PDA cells, resistant
cell lines constitutively expressed high levels of MxA and OAS,
two important IFN-stimulated antiviral proteins.
We previously showed that while the majority of tested PDA
cell lines were highly susceptible to VSV-DM51-GFP, ﬁve of these
cell lines (BxPC-3, CFPAC-1, HPAC, HPAF-II and Hs766T) and the
non-malignant pancreatic duct epithelial cell line HPDE were at
least somewhat resistant to VSV-DM51-GFP mediated oncolysis
(Murphy et al., 2012). The same pattern of resistance was also
observed for wt VSV and VSV-p1-GFP, with a minor deviation for
wt VSV in that HPDE and CFPAC were more susceptible than
AsPC-1 and T3M4 (Murphy et al., 2012). These phenotypes were
conﬁrmed here for VSV-DM51-GFP (Figs. 7 and 8). However, it
should be noted that BxPC-3, previously shown to be highly
resistant to VSV (Murphy et al., 2012), was omitted from this
study as it displayed an unstable phenotype, being generally
resistant but occasionally highly susceptible to VSV-DM51-GFP.
Even though passage numbers were limited for all tested cell
lines, we observed that increased passage number tended to
correlate with increased susceptibility of BxPC-3 to VSV-DM51-
GFP suggesting alterations in cell biology may be responsible for
this variability. BxPC-3 cells in culture have been shown to
Fig. 6. Effect of JAK/STAT signaling inhibition on PDA cell viability following infection. (A) Cells were mock (DMSO) treated or treated with 0.5 or 2.5 mM JAK Inh. I for
48 h prior to infection with VSV-DM51-GFP at MOI 1 CIU/cell. Cell viability was analyzed by MTT assay at 5 d p.i. and is expressed as a percent of the DMSO only (mock)
control. (B) The same assay was also performed in parallel with viable cell counts. The assays were done in triplicate and data represent the mean7standard error of mean.
Treatments were compared using a 1-way ANOVA followed by the Bonferroni posttest for multiple comparisons. Within each cell line, the presence of the same letter
above a bar indicates treatments are not statistically different (cut-off po0.05). For example, a bar marked ‘‘ab’’ does not differ from one marked ‘‘a’’ or ‘‘b’’ but is
signiﬁcantly different from one marked ‘‘c’’.
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Interestingly, our previous study showed BxPC-3 differed from
the other highly resistant cell lines in that secretion of IFN-b was
not detectable following VSV infection (Murphy et al., 2012).
Further studies are needed to better understand the BxPC-3
phenotype.
In order to mount an effective IFN mediated antiviral response,
cells must ﬁrst detect the virus. For RNA viruses replicating in the
cytoplasm, such as VSV, detection occurs primarily through
binding of single or double stranded viral RNA to RIG-I or
melanoma differentiation associated gene 5 (MDA5) (Nakhaei
et al., 2009; Shmulevitz et al., 2010). This initiates a signaling
cascade resulting in phosphorylation of IRF 3 and 7 and formation
of homo- and heterodimeric transcription factors necessary
for expression of the type I IFNs a and b. Both of these secreted
IFNs bind to the IFNAR1/2 receptor of the infected as well as
surrounding non-infected cells, resulting in phosphorylation of
the receptor by the Janus kinases JAK1 and TYK2. This results in
recruitment and phosphorylation of STAT1 and STAT2 which
together with IRF9 form a transcription factor, ISGF3, which
recognizes IFN-stimulated response elements (ISRE) leading to
transcription of ISGs, many of which have direct antiviral func-
tions or contribute to the formation of an antiviral state. Several
of these ISGs, including ISG15, MxA, OAS and PKR, have been
shown to effectively inhibit replication of rhabdoviruses such as
VSV (Sadler and Williams, 2008).
The high sensitivity of VSV to type I IFN responses is a major factor
determining VSV’s oncoselectivity, as it is believed most cancer cells
are defective in type I IFN responses (Naik and Russell, 2009; Stojdl
et al., 2000). However, some cancers retain the ability to produce
and/or respond to type I IFN (Naik and Russell, 2009; Stojdl et al.,2000). For example, PC3 prostate cancer cells (Ahmed et al., 2004;
Carey et al., 2008), SW982 human sarcoma cells (Paglino and van den
Pol, 2011), RT-4 and RT112 bladder cancer cells (Zhang et al., 2010),
and multiple mesothelioma cells lines (Saloura et al., 2010) have been
shown to be resistant to VSV infection at least in part due to IFN
responsiveness and/or constitutive ISG expression. Furthermore, con-
stitutive ISG expression was shown to be predictive of permissiveness
of several PDA cell lines to adenovirus infection (Monsurro et al.,
2010). Given this and our previous data demonstrating many
resistant PDA cell lines both produce and respond to type I IFN
(Murphy et al., 2012), as does the ‘‘normal’’ non-malignant HPDE cell
line, we examined the responses of these cell lines to VSV-DM51-GFP
at the molecular level. All tested cell lines appeared to be able to
sense VSV-DM51-GFP as seen by production of IFN-l mRNA and an
increase in IRF3 phosphorylation following infection, even in cell lines
where IFN-a and/or b transcription is not induced (Figs. 1 and 2).
STAT1 phosphorylation was detected in response to VSV-
DM51-GFP infection in the resistant cell lines and in the suscep-
tible cell lines AsPC-1 and Suit2, although the response in Suit2
was not robust. In the susceptible Mia PaCa-2 cells, STAT1 was
phosphorylated in response to exogenously added IFN-a but not
to VSV-DM51-GFP, suggesting the inability of this cell line to
produce type I IFN (possibly due to poor IRF7 expression).
Importantly, MxA was constitutively expressed at both the
mRNA and protein level in all resistant cell lines but in none of
the susceptible cell lines. MxA has broad antiviral activity against
a wide range of RNA and even some DNA viruses, regardless of
subcellular site of replication (Haller and Kochs, 2011). It is believed
that MxA GTPases recognize viral RNP complexes and form
oligomeric rings around them, thereby blocking their function.
MxA has also been implicated in the hyperphosphorylation of
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Fig. 7. Permissiveness of PDA cell lines to VSV-DM51-GFP, VVT7 and HSV-1.
Cells were infected with serial dilutions of virus and, after a 1 h absorption,
overlayed with media containing 0.5% BactoAgar. VSV-DM51-GFP foci were
counted by ﬂuorescent microscopy at 3 d p.i. VVT7 and HSV-1 plaques were
counted after staining with crystal violet at 5 d p.i. Titers are expressed relative to
those on Vero cells. A relative yield of 0 indicates that the PDA cell line and Vero
are equally permissive to the virus, while negative numbers indicate reduced
permissiveness on the PDA cell line. Plaque size was determined for all viruses at
5 d p.i. following crystal violet staining.
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1996). Constitutive expression of MxA (270-fold over baseline) was
observed in the SW982 sarcoma cell line resistant to VSV (Paglino
and van den Pol, 2011). Similarly, increased expression of MxA in
PDA cells was recently associated with resistance to adenovirus-
based OV (Monsurro et al., 2010). Furthermore, OAS wasconstitutively expressed in all the resistant cell lines as well as a
few susceptible cell lines, at least at the mRNA level, although the
highest levels were detected in resistant cell lines. OAS converts
adenosine triphosphate into a series of 20–50 oligoadenylates (2–
5A), which activate the latent ribonuclease (RNaseL). The activated
OAS-RNaseL system promotes apoptosis, attenuates proliferation,
degrades viral and cellular RNA, and inhibits protein synthesis
(Justesen et al., 2000; Mandal et al., 2011). Previous studies showed
increased expression of OAS in PDA cells resistant to adenoviruses
(Monsurro et al., 2010), and human mesothelioma cells resistant to
VSV (Saloura et al., 2010). As both MxA and OAS have been shown
to have antiviral activity against VSV, they almost certainly con-
tribute to the resistance phenotype of the PDA cells studied here.
However, as there are hundreds of ISGs, a number of which also
have known antiviral functions (Sadler and Williams, 2008), resis-
tance is likely to involve more than just these two proteins.
It is unclear why these proteins are expressed constitutively
at high levels. While low levels of phosphorylated STAT1 were
detected in some uninfected resistant cell lines, it is uncertain
whether these levels were sufﬁcient for the observed expression
of MxA and other ISGs in uninfected cells. However, the strong
reduction in MxA and OAS protein levels upon inhibition of
JAK/STAT signaling (Fig. 3) would argue the effect is at least partially
mediated through this mechanism. It is also not clear why not all
resistant cell lines constitutively express all of the ISGs tested, since
the ISGs are all under the control of ISREs. One possibility is that
alternative regulatory mechanisms inﬂuence expression of some of
these genes. For example, RelA has been shown to regulate a subset of
ISGs (Basagoudanavar et al., 2011). IFN-l is also known to regulate
ISG expression, although it regulates those genes through the same
mechanisms as type I IFN and the resulting ISG expression proﬁle is
thought to be nearly identical (Donnelly and Kotenko, 2010). Expres-
sion of these genes may also be inﬂuenced by chromosome modiﬁca-
tion as treatment with a histone deacetylase inhibitor was shown to
decrease ISG expression and increase VSV infectivity in the SW982
human sarcoma cell line (Paglino and van den Pol, 2011).
In our study, ﬁve of the 11 human PDA cell lines tested showed
constitutive expression of the ISGs MxA and OAS. While this collec-
tion of cell lines is likely not representative of the clinical situation, a
recent study showed that a signiﬁcant subset of the bulk PDA tissues
and xenografted primary PDA cells tested had an mRNA expression
proﬁle typical of an inﬂamed state including upregulation of ISGs
such as MxA (Monsurro et al., 2010), demonstrating the existence
of this phenotype in the patient population. In addition, we have
identiﬁed a number of cell lines able to respond to type I IFN (Murphy
et al., 2012) as well as produce type I IFN in response to VSV-DM51-
GFP. While all of these cell lines were susceptible to VSV-DM51-GFP
in vitro, results presented here suggest that the type I IFN respon-
siveness of these cells may lead to suboptimal VSV-DM51-GFP
oncolysis. For example, virus-directed GFP expression increased in
both AsPC-1 and Suit2 upon JAK Inh. I treatment (Fig. 5) and AsPC-1
plaque size increased when the higher concentration of inhibitor was
used (data not shown).
Given these phenotypes, our results suggest that high constitutive
expression of ISGs may be useful biomarkers in identifying PDAs, and
possibly other cancers, resistant to OV therapy with VSV or other
viruses highly sensitive to IFN. In our study, the ISGs MxA and OAS
were particularly well correlated with this phenotype. While PDAs
with this proﬁles are unlikely to be successfully treated with IFN
sensitive OVs such as VSV, use of alternative OVs (e.g., vaccinia virus
or HSV-1), better equipped to evade IFN responses could be a better
option. Alternatively, treatment with more than one OV (combined
virotherapy) could also lead to enhanced oncolysis as was previ-
ously shown for VSV in combination with vaccinia virus (Le Boeuf
et al., 2010). Furthermore, any future OV therapy will likely involve a
combination of OV(s) and chemotherapy (Ottolino-Perry et al., 2010).
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Fig. 8. PDA cell viability following infection with VSV-DM51-GFP, VVT7 and HSV-1. Cells were mock infected or infected with VSV-DM51-GFP, VVT7 or HSV-1 at MOI of
1 (A) or 0.01 (B) CIU/cell. Cell viability was analyzed by an MTT assay at 5 d p.i. and expressed as a percent of mock-infected controls. MTT assays were done in triplicate
and the data represent the mean7standard error of mean.
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resistance of PDA cells to VSV-DM51-GFP infection, we cannot rule
out the possible inﬂuence of other factors on susceptibility and/or
oncolysis. For example, VSV has been shown to cause cell death via
apoptosis (Cary et al., 2011; Gaddy and and Lyles, 2005, 2007; Sharif-
Askari et al., 2007), and inhibition of apoptosis, a signature of many
cancer cells (Hamacher et al., 2008), has the potential of limiting/
delaying cell death following VSV infection. Studies are in progress
examining the role apoptosis and other factors may have in con-
tributing to the resistance of some PDAs to oncolytic VSV.Materials and methods
Cell lines
The human PDA cell lines used in this study were: AsPC-1
(ATCC CRL-1682), Capan-1 (ATCC HTB-79), Capan-2 (ATCC HTB-
80), CFPAC-1 (ATCC CRL-1918), HPAC (ATCC CRL-2119), HPAF-II
(ATCC CRL-1997), Hs766T (ATCC HTB-134), MIA PaCa-2 (ATCC
CRL-1420), Panc-1 (ATCC CRL-1469), Suit2 (Iwamura and Katsuki,
1987) and T3M4 (Okabe and Yamaguchi, 1983). In addition, a
non-malignant human pancreatic duct epithelial (HPDE) cell line
(Furukawa et al., 1996) was used and maintained in Keratinocyte-
SFM (K-SFM, Gibco). This cell line was generated by introduction
of the E6 and E7 genes of human papillomavirus 16 into
normal adult pancreas epithelium, retains a genotype similar to
pancreatic duct epithelium and is non-tumorigenic in nude mice
(Furukawa et al., 1996). The mouse breast cancer cell line 4T1
(ATCC CRL-2539), baby hamster kidney BHK-21 ﬁbroblasts (ATCC
CCL-10) and African green monkey kidney Vero cells (ATCC
CCL-81) were used to grow viruses and/or as controls. Capan-1,
CFPAC-1, HPAC, MIA PaCa-2, Panc-1, Suit2, 4T1 and Vero cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Cellgro). AsPC-1, Capan-2 and T3M4 cells were maintained inRPMI 1640 (HyClone). HPAF-II and BHK-21 cells were maintained
in modiﬁed Eagle’s medium (MEM, Cellgro). All cell growth media
were supplemented with 9% fetal bovine serum (FBS, Gibco),
3.4 mM L-glutamine, 900 U/ml penicillin and 900 mg/ml strepto-
mycin (HyClone). MEM was further supplemented with 0.3%
glucose (w/v). K-SFM was never supplemented with serum. Cells
were kept in a 5% CO2 atmosphere at 37 1C. For all experiments,
PDA cell lines were passaged no more than 10 times.
Viruses
The following viruses were used in this study: VSV-DM51-GFP,
vaccinia virus expressing T7 (VVT7) and herpes simplex virus type
1 (HSV-1) (MacIntyre strain; ATCC, VR-539). VSV-DM51-GFP has
a deletion of methionine at amino acid position 51 of the M
protein and the green ﬂuorescent protein (GFP) ORF inserted at
position 5 of the viral genome (Wollmann et al., 2010). VVT7 was
created by integration of the bacteriophage T7 RNA polymerase
into the vaccinia virus (strain Western Reserve) thymidine kinase
gene (Fuerst et al., 1986). VSV-DM51-GFP was grown on BHK-21
while VVT7 and HSV-1 were grown on Vero. Viral titers were
determined by standard plaque assay on 4T1 and/or Vero cells
and expressed as cell infectious units (CIU) per ml.
RNA analysis
Cells were either mock-treated, infected with VSV-DM51-GFP at
MOI of 10 CIU per cell (based on 4T1) or treated with 5000 U/ml
IFN-a (Calbiochem, 407294). Total RNA was extracted from cells
at 4 or 12 h post-infection (p.i.) using the Quick-RNA Mini Prep kit in
accordance with manufacturer instructions (Zymo Research). 0.5 mg
of total RNA per reverse transcription (RT) reaction using SMART-
Scribe reverse transcriptase (Clontech) was used for the cDNA
synthesis as per manufacturer’s protocol. PCR was carried out on this
cDNA using the following conditions: denaturation at 94 1C for 45 s,
M. Moerdyk-Schauwecker et al. / Virology 436 (2013) 221–234232annealing at 57 1C for 45 s, extension at 72 1C for 45 s for either 25, 30
or 35 cycles and a ﬁnishing step at 72 1C for 8 min. All primers for PCR
are shown in the Supplementary Table 1 and were designed to not
amplify genomic DNA. PCR products were electrophoresed on a 2%
agarose gel with ethidium bromide and photographed using a
GelDoc-It imager (UVP Imaging, Upland, CA).
Western blot
Cellular lysates were prepared from cells either mock-treated,
infected with VSV-DM51-GFP at MOI 10 CIU/cell (based on 4T-1)
or treated with 5,000 U/ml IFN-a. At 1 h p.i., virus was aspirated
and cells were extensively washed and incubated in growth
media containing 5% FBS. Cells were harvested at 12 h p.i.
and lysed in lysis buffer (pH 7.5) containing 1% Triton-X-100,
20 mM Hepes, 0.15 M NaCl, 2 mM EDTA and supplemented with
c-inhibitor (2X, Roche) and Phosphatase Inhibitor Cocktail
2 (Sigma-Aldrich). Total protein concentration was determined
by Bradford assay. Twenty mg of total protein was separated
by electrophoresis on 10% SDS-PAGE gels and electroblotted
to polyvinylidene diﬂuoride (PVDF) membranes. Membranes
were blocked using 5% non-fat powdered milk in TBS-T [0.5 M
NaCl, 20 mM Tris (pH 7.5), 0.1%Tween20]. Membranes were
incubated with 1:5000 rabbit polyclonal anti-VSV antibodies
(raised against VSV virions), 1:1000 rabbit anti-MX1 (Sigma-
Aldrich, SAB1100070), 1:200 rabbit anit-OAS2 (Santa Cruz, sc-
99097), 1:3000 mouse anti-GFP (Rockland, 600-301-215), and the
following antibodies from Cell Signaling (1:1000): anti-STAT1
(9172), Stat1-P (9171), Stat2 (4594), Stat2-P (4441), IRF3 (4302),
IRF3-P (4947), eIF2a (5324), and eIF2a-P (3398) in TBS-T with 5%
BSA. Detection was with 1:2000 goat anti-rabbit or 1:5000 goat
anti-mouse horseradish peroxidase-conjugated secondary antibo-
dies (Jackson ImmunoResearch, 111-035-003 and 115-035-003,
respectively) using the Enhanced Chemiluminescence Plus
(ECLþ) protein detection system (GE Healthcare). Membranes
were reprobed with mouse anti-actin antibody (clone C4) (Moyer
et al., 1986) to verify sample loading.
JAK inhibition
For new infectious particle production, 6-well plates were
seeded such that they were approximately 80% conﬂuent at the
time of inhibitor treatment. Cells were pretreated with 0.5 or
2.5 mM JAK inhibitor I (Jak Inh. I, Calbiochem) or vehicle (DMSO)
only in cell culture media with 5% FBS (K-SFM was used without
FBS) for 48 h prior to infection (media was removed and
replaced with fresh drug/vehicle containing media after the ﬁrst
24 h). Cells were then mock infected or infected with VSV-
DM51-GFP in DMEM without FBS at an MOI of 10 CIU/cell (based
on 4T1). Following a 1 h absorption period, the virus containing
media was aspirated, cells were washed three times with PBS
and growth media with 5% FBS containing either 0.5 or 2.5 mM
JAK Inh. 1 or vehicle was added to the wells. At 16 h p.i., media
was collected and used for a standard plaque assay on BHK-21
cells. Cells treated and infected in the same manner were
also used to prepare cellular lysates for western blotting as
described above.
For plaque and cell viability assays, cells were seeded in
96-well plates such that they were approximately 80% conﬂuent
at the time of inhibitor treatment, and pretreated for 48 h with
JAK Inh. I as described above. For the plaque assay, cells were then
infected with 8-fold serial dilutions of VSV-DM51-GFP in DMEM
without FBS. Following a 1 h absorption period, the virus contain-
ing media was aspirated and replaced with cell culture media
containing 5% FBS and either JAK Inh. I or vehicle. At 17 h p.i.,
ﬂuorescent foci were visualized and counted using ﬂuorescentmicroscopy. For the cell viability assay, following pretreatment,
cells were mock infected or infected with VSV-DM51-GFP in
DMEM without FBS at a MOI of 1 CIU/cell (based on 4T1).
Following a 1 h absorption period, the virus containing media
was aspirated and replaced with growth media with 5% FBS
containing either 0.5 or 2.5 mM JAK Inh. 1 or vehicle. GFP ﬂuor-
escence was measured every 24 h using a CytoFluor multi-well
plate reader (PerSeptive Biosystems) with excitation ﬁlter of
450/50 nm, emission ﬁlter of 530/25 nm and gain¼50. At 5 days
(d) p.i., cell viability was analyzed using a 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) cell viabi-
lity assay (Biotium) in accordance with manufacturer instructions.
Permissiveness of cells to different viruses
Cells were seeded in 24-well plates such that they were approxi-
mately 90% conﬂuent at the time of infection. Cells were infected
with 8-fold serial dilutions of VSV-DM51-GFP, VVT7, or HSV-1 in
DMEM without FBS for 1 h. Virus was aspirated and cells were
overlaid with the appropriate growth media containing 5% FBS and
0.5% BactoAgar. For VSV-DM51-GFP, ﬂuorescent foci were visualized
at 3 d p.i. by ﬂuorescent microscopy. For all viruses, at 5 d p.i. cells
were ﬁxed by addition of 350 ml 10% neutral buffered formalin
(Sigma-Aldrich) to each well. Following a 1 h incubation at room
temperature, the agar was gently removed and cells stained with 1%
crystal violet in 20% methanol to allow visualization of plaques.
Cell viability following infection with different viruses
Cells were seeded in 96-well plates such that they were
approximately 80% conﬂuent at the time of infection. Cells were
mock infected or infected with VSV-DM51-GFP, VVT7, or HSV in
SFM-MegaVir, at an MOI of 1 or 0.01 CIU/cell (based on Vero).
Following a 1 h absorption period, the virus containing media was
aspirated and replaced with growth media containing 5% FBS.
At 5 d p.i., cell viability was analyzed using an MTT cell viability
assay (Biotium) in accordance with manufacturer instructions.
Statistical analysis
All statistical analyses were performed using GraphPad Prism,
version 5.03 for Windows (GraphPad Software, San Diego,
California). Comparisons within a cell line following treatment
were made using a one-way ANOVA with Bonferroni post-test.Acknowledgments
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